We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GlaxoSmithKline plc (GSK - Free Report) with partner, Innoviva, Inc. (INVA - Free Report) , announced that it has accelerated the timeline for filing a New Drug Application (NDA) for the once-daily closed triple combination therapy (FF/UMEC/VI) for the treatment of patients with chronic obstructive pulmonary disease (COPD).
The closed triple therapy is a combination of an inhaled corticosteroid (fluticasone furoate/FF), a long-acting muscarinic antagonist (umeclidinium/UMEC) and a long-acting beta agonist (vilanterol/VI).
Following discussions with the FDA, the companies brought the regulatory filing forward to the end of 2016 from the first half of 2018. However, the EU regulatory submission is still expected to be made by the end of 2016.
The companies stated that the NDA would consist of data currently in hand from the closed triple combination therapy development program and results from studies on FF, UMEC and VI either alone or in combination.
We note that the closed triple combination therapy is currently being evaluated in two phase III studies – FULFIL and IMPACT – designed to assess the safety and the effectiveness of the combination, in comparison with existing COPD treatments. Data from the FULFIL study are expected later in 2016, while results from the IMPACT study are anticipated in 2017.
Glaxo’s acceleration of the NDA filing is a big positive for Theravance Biopharma, Inc. (TBPH - Free Report) , as the latter has an economic interest in future payments, pursuant to its agreement with Innoviva for certain drug development programs.
Per the agreement, Theravance Biopharma is entitled to receive 85% economic interest in royalties paid by Glaxo in worldwide net sales. The royalties are upward-tiering from 6.5% to 10%.
Meanwhile, Innoviva retains a 15% economic interest in future payments made by Glaxo.
Currently, both Glaxo and Innoviva carry a Zacks Rank #3 (Hold). Bristol-Myers Squibb Company (BMY - Free Report) is a better-ranked stock in the health care sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
GlaxoSmithKline plc (GSK - Free Report) with partner, Innoviva, Inc. (INVA - Free Report) , announced that it has accelerated the timeline for filing a New Drug Application (NDA) for the once-daily closed triple combination therapy (FF/UMEC/VI) for the treatment of patients with chronic obstructive pulmonary disease (COPD).
The closed triple therapy is a combination of an inhaled corticosteroid (fluticasone furoate/FF), a long-acting muscarinic antagonist (umeclidinium/UMEC) and a long-acting beta agonist (vilanterol/VI).
Following discussions with the FDA, the companies brought the regulatory filing forward to the end of 2016 from the first half of 2018. However, the EU regulatory submission is still expected to be made by the end of 2016.
The companies stated that the NDA would consist of data currently in hand from the closed triple combination therapy development program and results from studies on FF, UMEC and VI either alone or in combination.
We note that the closed triple combination therapy is currently being evaluated in two phase III studies – FULFIL and IMPACT – designed to assess the safety and the effectiveness of the combination, in comparison with existing COPD treatments. Data from the FULFIL study are expected later in 2016, while results from the IMPACT study are anticipated in 2017.
Glaxo’s acceleration of the NDA filing is a big positive for Theravance Biopharma, Inc. (TBPH - Free Report) , as the latter has an economic interest in future payments, pursuant to its agreement with Innoviva for certain drug development programs.
Per the agreement, Theravance Biopharma is entitled to receive 85% economic interest in royalties paid by Glaxo in worldwide net sales. The royalties are upward-tiering from 6.5% to 10%.
Meanwhile, Innoviva retains a 15% economic interest in future payments made by Glaxo.
Currently, both Glaxo and Innoviva carry a Zacks Rank #3 (Hold). Bristol-Myers Squibb Company (BMY - Free Report) is a better-ranked stock in the health care sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>